Eddie Hickman
Stock Analyst at Guggenheim
(4.37)
# 379
Out of 5,030 analysts
17
Total ratings
62.5%
Success rate
19.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eddie Hickman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OTLK Outlook Therapeutics | Downgrades: Neutral | n/a | $1.31 | - | 4 | Aug 29, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Buy | $78 → $84 | $72.93 | +15.18% | 8 | May 2, 2025 | |
| PMN ProMIS Neurosciences | Reiterates: Buy | $6 | $0.44 | +1,271.12% | 2 | Apr 1, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $20 → $22 | $10.81 | +103.61% | 1 | Mar 13, 2025 | |
| GHRS GH Research | Initiates: Buy | $32 | $13.49 | +137.21% | 1 | Mar 13, 2025 | |
| CYBN Cybin | Initiates: Buy | $35 | $6.03 | +480.43% | 1 | Mar 13, 2025 |
Outlook Therapeutics
Aug 29, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.31
Upside: -
Tarsus Pharmaceuticals
May 2, 2025
Maintains: Buy
Price Target: $78 → $84
Current: $72.93
Upside: +15.18%
ProMIS Neurosciences
Apr 1, 2025
Reiterates: Buy
Price Target: $6
Current: $0.44
Upside: +1,271.12%
Zevra Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $20 → $22
Current: $10.81
Upside: +103.61%
GH Research
Mar 13, 2025
Initiates: Buy
Price Target: $32
Current: $13.49
Upside: +137.21%
Cybin
Mar 13, 2025
Initiates: Buy
Price Target: $35
Current: $6.03
Upside: +480.43%